Replimune Group (REPL) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
9 Jul, 2026Opening remarks and agenda
Meeting commenced with a welcome and introduction of the Executive Chairman and key legal and accounting representatives.
Legal formalities were addressed to ensure the meeting was duly authorized.
The Inspector of Elections was introduced and took charge of proxies.
Board and executive committee updates
Directors and officers were introduced, including the CEO, Lead Independent Director, and CFO.
Shareholder proposals
Proposals included the election of five Class I Directors, ratification of the accounting firm, advisory approval of executive compensation, and an amendment to the 2018 Omnibus Incentive Plan.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Replimune Group
- FDA accelerated approval of TUDRIQEV drives launch and extends cash runway for over a year.REPL
Q1 2027 - FDA accelerated approval of TUDRIQEV plus nivolumab offers new hope for advanced melanoma post-PD-1.REPLFDA announcement
- A novel oncolytic virus plus nivolumab shows strong efficacy and safety in advanced melanoma.REPLInvestor presentation
- Stockholders will vote on auditor ratification, executive pay, and doubling authorized shares.REPLProxy filing
- Shareholders will vote on auditor ratification, executive pay, and doubling authorized shares.REPLProxy filing
- Registering 25.1M shares for resale, the company faces regulatory and financial uncertainty.REPLRegistration filing
- Stockholders will vote on auditor ratification, executive pay, and doubling authorized shares.REPLProxy filing
- RP1 plus nivolumab achieved a 33.6% ORR and durable responses in anti-PD1 failed melanoma.REPLStudy Result
- RP1 shows 34% response in anti-PD-1 failed melanoma, with global launch and expansion planned.REPL43rd Annual J.P. Morgan Healthcare Conference 2025